QuneUp®

Are you tired of never having the process equipment information when you need it? Is that information buried in an email somewhere? In the back of a dusty doc room? What if there was a way to reduce equipment downtime and boost productivity. Ready to give your data a QuneUp™? It's easy! Snap and go! Visit us at quneup.com to learn more.

Our most recent Meet the Innovator features Simone Ammons, Founder and CEO of QuneUp®! QuneUp® is a data-driven software tool that reduces equipment down time by enabling access to critical data. Ammons is a Process Engineer who was frustrated with rarely having the critical process equipment data they needed at the right time. Every minute spent digging for equipment specification sheets and manuals, was a minute that the production line was down – racking up costs for the company. Learn more about Simone in the video below or read the full interview here: https://bit.ly/4eVmz2L

You can now view the Q&A with QuneUp series on our website: https://lnkd.in/eQvm_iFP Each week, topics in the Life Science and biopharmaceutical manufacturing industry are shared, all within 2 minutes or less. The goal is to break down these complex topics into bite sized pieces that's easier to digest. Stay tuned!

In this video, see how easy it is to get access to your equipment information using QuneUp™. All you need is a cell phone or other camera enabled device. Scan the QuneUp QR code. Access your critical equipment information. Start your troubleshooting process. And then get back to Production. Equipment. Data. Digitalized. Give your data a QuneUp.

The Big Bad Bs in Biopharmaceutical Manufacturing. BPA and bDtBPP. You've probably heard of BPA when it comes to plastic utensils. BPA is an unwanted byproduct from polymer (plastic) production. BPA looks and acts estrogen and has been linked to a number of health issues, leading to it being banned in the production of drinking water bottles and baby bottles. Nowadays, most plastic utensils are now labeled as BPA-free. In the biopharmaceutical industry, the issue is with bDtBPP. bDtBPP is an unwanted byproduct from the manufacture of polymer bags used in single use bioreactors. You can learn more about the differences between traditional and single use bioreactors in our previous post: https://lnkd.in/eiz3cYwb bDtBPP has been shown to slow down cell growth - the exact opposite of what you want to happen in a bioreactor. Biopharm companies need to be extremely careful when deciding to switch from traditional bioreactors to single use bioreactors. Swipe through the guide below to learn more about the ways you can overcome the challenges to cell growth when using single use polymer bags in biopharmaceutical manufacturing. #biopharmaceuticalmanufacturing #singleusebioreactors #traditionalbioreactors #processengineering #quality

In biopharmaceutical manufacturing, single use bioreactors that use polymer (plastic) bags are becoming an increasingly popular choice over traditional stainless steel bioreactors. The mission of both styles of bioreactors are the same: To maximize cell growth and production output. However, there are many pros and cons to each type of bioreactor. See below for a detailed comparison of both types of bioreactors.

In 2023, the FDA issued 510 Warning Letters in the Drug category, and 45 Warning Letters in the Biologics category. An analysis of the citations from 2023 show an interesting trend in the words most commonly used in the 483 Warning Letters issued by the FDA. See video below to learn more. It's important to keep a close eye on what keeps coming up in these Warning Letters. These Warning Letters can help you better understand what the FDA is keeping their pulse on during inspections and site visits. Are you FDA audit ready? #pharmaceuticalmanufacturing #quality #processengineering #auditprep #processequipment #deviations

Is your facility FDA audit ready? A look at back at the last decade in the numbers of FDA 483 Warning Letters issued show a significant dip during the height of the pandemic. FDA 483 Warning Letters are issued following a site visit when conditions found do not meet FDA's stringent regulations. The numbers of FDA 483 Warning Letters being issued have started to rebound. A couple of questions to think about: Are all critical equipment and instrument calibrations up to date? Are your training and onboarding processes effective? Are deviations addressed in a timely manner? Are your SOPs clear and up to date? Are effective CAPAs in place? Now might be a good time to get your house in order. Your next FDA audit is most likely to be sooner rather than later. As they say, stay ready so you don't have to get ready. #pharmaceuticalmanufacturing #fdacompliance #processengineering #deviations #auditready #equipmentmanagement

The 2024 Philly RealLIST Startups have been announced! Pennovation members Sonura, Pocket Scribe, and QuneUp™, as well as Accelerator alumni startups, Baleena and Vertige - The Vertigo Tracker were recognized. Read more about the companies that have experienced major growth within the past year below. #PhillyStartups #PhillyTech #Innovation

On Tuesday, three Pennovation Works member companies participated in a panel hosted by the University of Pennsylvania's Graduate Association of Bioengineers (GABE) to discuss bioengineering PhD career paths outside of traditional academia. Bob Shultz, PhD of Axonova Medical, Kyle Palmer, PhD of Opertech Bio, and Simone Ammons of QuneUp™, discussed current trends in bioengineering that could affect students entering the workforce, the importance of internships in helping to find a position post-grad, and how the industry is changing to incorporate new technologies like AI. It’s always great to see our member companies inspiring the next generation of innovators! #pennovationinpictures #biomedicalengineering #careers